United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New York-based drugmaker said Monday it has commenced a new large study that will evaluate a novel protease inhibitor “PF-07321332” for effectiveness in preventing COVID-19 infection.

Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus

Valneva SE

Saint- Herblain ( France) and New York (United States) , September 28 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced further positive Phase 2 results, including booster response, for Lyme disease vaccine candidate VLA15.

Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate

Eli Lilly

Novavax

If the COVID mutation takes a turn for the worse, what stocks will protect your port? Our trio of Fools has three suggestions.

3 COVID Stocks Ready to Take On the Delta Variant

Pfizer Inc. (PFE) CEO Albert Bourla on Cantor Global Healthcare 2021 Conference (Transcript)

NEW YORK--(BUSINESS WIRE)--Start of influenza mRNA study

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program

Pfizer hopes the pill, taken twice a day, would stop someone from becoming infected with Covid-19.

Pfizer Tests Pill That Could Prevent Covid Infection

Pfizer Inc (NYSE: PFE) has started the Phase 2/3 EPIC-PEP study to evaluate its oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.  Related:   COVID-19 Oral Antiviral Drug From Pfizer Could Be Available By 2021, Says CEO: CNBC.

Pfizer Kick Starts Late-Stage Study For COVID-19 Oral Antiviral For Post-Exposure Prophylaxis

Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.  The FDA has pushed back approval of Pfizer's once-weekly prospect.

Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months

Pfizer Inc. PFE, -0.57% said Monday it is starting a Phase 2/3 trial of its investigational novel oral antiviral candidate to treat adults living in a household with someone who has tested positive for and has symptoms of the coronavirus-borne illness COVID-19. The candidate is called PF007321332 and is co-administered with a low dose of ritonavir to prevent infection.

Pfizer starting trial for oral drug to be taken after COVID-19 exposure

NEW YORK--(BUSINESS WIRE)--Antiviral prophylactic study start.

Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults

Pfizer is just manufacturing Comirnaty, a COVID-19 vaccine, but has other vaccines in the pipeline that could give its results, and PFE stock, a real shot in the arm. The post Pfizer Stock: Vaccine Crown Not Enough as Profit King Status Comes Next appeared first on InvestorPlace.

Pfizer Stock: Vaccine Crown Not Enough as Profit King Status Comes Next

Pfizer sells the leading COVID-19 vaccine -- and seven other blockbusters.

Thinking of Buying Pfizer Stock? Here's What You Need to Know

Pfizer Inc (NYSE: PFE) CEO Albert Bourla said that there is a likelihood that annual booster shots of the coronavirus vaccine will be needed. What Happened: Bourla said in an interview with ABC's “This Week” program that the COVID-19 vaccine could morph into an annual shot.

Pfizer CEO Says People Needing COVID-19 Vaccines Every Year Is The 'Most Likely Scenario'

Once it's submitted, the FDA is expected to take approximately four to six weeks before it decides whether to approve the shots.

Child Covid-19 Vaccine Data Will Be Submitted To FDA Within ‘Days,' Pfizer CEO Says

The US Food and Drug Administration last week authorized Pfizer boosters for people 65 years and older and others at high risk of severe COVID-19,

Pfizer CEO predicts 'we will able to come back to normal life' within a year even with new variants of the coronavirus

Pfizer CEO Albert Bourla said "within a year," normal life will return, and we may need annual Covid shots, in an interview on ABC's "This Week."

Pfizer CEO Albert Bourla predicts normal life will return within a year and adds we may need annual Covid shots

Johnson & Johnson

Procter & Gamble

Target

These stocks are Dividend Kings for a reason, and they look really well poised to grow manifold in the coming years.

5 Top Dividend Kings to Buy Now and Hold Forever

CDC Director Dr. Rochelle Walensky insisted Friday she didn't overrule a vaccine advisory committee by expanding the agency's approval of Pfizer's Covid boosters to include a proposal rejected by the panel.

CDC director defends unusual decision on Pfizer's Covid boosters: 'It was a scientific close call'

The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.

Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only

First Trust Natural Gas ETF

Amplify Treatments Testing & Advancements ETF

Invesco Dynamic Energy Exploration & Production ETF

VanEck Rare Earth/Strategic Metals ETF

Sprott Uranium Miners ETF

SPDR S&P Retail ETF

Invesco S&P SmallCap Value with Momentum ETF

We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.

7 Best ETFs of the First Nine Months of 2021

BioNTech SE

The decision is in line with FDA authorization for booster shots of the Pfizer-BioNTech vaccine.

CDC director endorses Pfizer booster for frontline workers, overruling advisory panel

The Centers for Disease Control and Prevention (CDC) backed a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for Americans aged 65 and older and adults with an underlying medical condition. It also said that residents of nursing homes and other long-term-care facilities should also get the extra shots.

Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends

Dr. Rochelle Walensky recommended workers in high-risk settings to also be offered Pfizer Covid booster doses, despite the CDC advisers voting against this group getting the third shot.

CDC Director Backs Pfizer Booster Shots For Seniors, Vulnerable—And High-Risk Workers

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

An advisory committee to the agency rejected a recommendation for boosters for people aged 18 to 64 in an occupational or institutional setting where the risk of transmission is high.

News for Pfizer Stock (PFE)